0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-300.00%PremiumJul 19, 2024Expiry Date3.75Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.45Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Kronos Bio Stock Discussion
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
• $Cogent Biosciences(COGT.US)$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US)$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US)$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US)$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
No comment yet